Hangzhou Tigermed
Hangzhou Tigermed Consulting Co., Ltd., commonly known as Tigermed, is a leading clinical research organisation headquartered in Hangzhou, China. Founded in 2004, the company has established a strong presence across Asia, Europe, and North America, providing comprehensive services in the pharmaceutical and biotechnology sectors. Tigermed specialises in clinical trial management, regulatory affairs, and data management, offering unique solutions that streamline the drug development process. With a commitment to quality and innovation, the company has achieved significant milestones, including numerous successful trials for global clients. Recognised for its expertise and reliability, Tigermed holds a prominent position in the industry, contributing to advancements in healthcare and supporting the development of new therapies. Its dedication to excellence has earned it a reputation as a trusted partner in clinical research.
DitchCarbon Score
How does Hangzhou Tigermed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hangzhou Tigermed's score of 22 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hangzhou Tigermed's reported carbon emissions
In 2023, Hangzhou Tigermed Consulting Co., Ltd. reported total carbon emissions of approximately 2,136,860 kg CO2e globally, with 94,270 kg CO2e from Scope 1 and 2,042,580 kg CO2e from Scope 2 emissions. In China, their emissions were significantly higher, totalling about 13,341,350 kg CO2e, comprising 124,060 kg CO2e from Scope 1 and 13,217,290 kg CO2e from Scope 2. Over the years, Tigermed has shown a trend of increasing emissions, with a total of 2,163,020 kg CO2e reported in 2022 globally, and 9,769,620 kg CO2e in China. The company has committed to near-term climate targets but has not set a net-zero commitment as of now. Tigermed operates within the Pharmaceuticals, Biotechnology, and Life Sciences sector and is actively working towards reducing its carbon footprint. The company has acknowledged its emissions and is in the process of developing strategies to address its climate impact, although specific reduction targets have not been disclosed.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 63,180 | 00,000 | 00,000 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | 1,037,878 | 0,000,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | 000 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hangzhou Tigermed is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
